 |
110 Diseases |  |
158 Trials |
|
158 Trials |  |
1691 News |  |
| «12...345678910111213...2728» |
- | goserelin acetate / Generic mfg.
Biomarker, Journal: The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis. (Pubmed Central) - Apr 6, 2022
Six months of goserelin-induced MC lead to significant bone loss associated with increased bone turnover and changes in the expression of bone-related miRNAs, changes that are only partially reversed at 6 m after MR.
- | goserelin acetate / Generic mfg.
Journal: Pharmacological hypogonadism impairs molecular transducers of exercise-induced muscle growth in humans. (Pubmed Central) - Apr 6, 2022
Six months of goserelin-induced MC lead to significant bone loss associated with increased bone turnover and changes in the expression of bone-related miRNAs, changes that are only partially reversed at 6 m after MR. We conclude that endogenous T sufficiency has a central role in the up-regulation of molecular transducers of RET-induced muscle hypertrophy in humans that cannot be overcome by muscle mechano-transduction alone.
- | goserelin acetate / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion: SEAT: Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients (clinicaltrials.gov) - Apr 6, 2022
P2, N=116, Completed, Sponsor: Shanghai Jiao Tong University School of Medicine
We conclude that endogenous T sufficiency has a central role in the up-regulation of molecular transducers of RET-induced muscle hypertrophy in humans that cannot be overcome by muscle mechano-transduction alone. Recruiting --> Completed
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: PATHWAY: PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY (clinicaltrials.gov) - Apr 6, 2022
P3, N=180, Active, not recruiting, Sponsor: National Cancer Center, Japan
Recruiting --> Completed Trial completion date: Feb 2022 --> Jul 2022 | Trial primary completion date: Feb 2022 --> Jul 2022
- || Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date: Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) - Apr 6, 2022
P4, N=137, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Feb 2022 --> Jul 2022 | Trial primary completion date: Feb 2022 --> Jul 2022 Trial completion date: Nov 2027 --> Feb 2028 | Trial primary completion date: Oct 2027 --> Jan 2028
- || Visanne (dienogest) / Mochida, Bayer
Clinical, Journal: A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea. (Pubmed Central) - Apr 5, 2022
GnRH-a is more effective in improving anemia and reducing the uterine volume in patients with adenomyosis. TRIAL REGISTRATION: ChiCTR1900024958.
- | tamoxifen / Generic mfg.
Retrospective data, Journal: Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. (Pubmed Central) - Apr 5, 2022
Using an aromatase inhibitor rather than tamoxifen in premenopausal women receiving ovarian suppression reduces the risk of breast cancer recurrence. Longer follow-up is needed to assess any impact on breast cancer mortality.
- || leuprolide acetate for depot suspension / Generic mfg.
Review, Journal: Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety. (Pubmed Central) - Apr 5, 2022
Goserelin appears to be the most convenient of all the GnRH-A for administration. Lack of conclusive comparative evidence makes it imperative to have a holistic approach of considering the patient profile and the disease characteristics to select the appropriate GnRH-A for ADT in prostate cancer.
- || Firmagon (degarelix) / Astellas, Ferring
Review, Journal: A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone-releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix). (Pubmed Central) - Apr 5, 2022
There is considerable long-term evidence for goserelin in patients with advanced PCa, with degarelix being a more recent option. The available comparative evidence of goserelin versus degarelix has several inherent limitations related to study design, sample size, conduct, and statistical analyses, and hence warrants robust prospective trials and long-term follow-up.
- | Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
New P4 trial: PRIZE: Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual. (clinicaltrials.gov) - Mar 31, 2022
P4, N=48, Completed, Sponsor: Zodiac Produtos Farmaceuticos S.A.
- ||| bicalutamide / Generic mfg.
Journal, Adverse events: Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the FDA adverse event reporting system. (Pubmed Central) - Mar 30, 2022
Based on this FAERS pharmacovigilance analysis, the association between ILD events and hormone therapy drugs, including bicalutamide, flutamide, nilutamide, goserelin, degarelix and apalutamide, should not be ignored, especially in Japanese population. Lung function of prostate cancer patients should be monitored when receiving hormone therapy drugs mentioned above, especially the first year post medication.
- ||| amcenestrant (SAR439859) / Sanofi, Ibrance (palbociclib) / Pfizer
Clinical, P3 data, Journal: AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. (Pubmed Central) - Mar 23, 2022
P3
AMEERA-5 is evaluating the efficacy and safety of amcenestrant in combination with palbociclib as first-line therapy in pre-/postmenopausal women and men with ER+/HER2- ABC. NCT04478266.
- goserelin acetate / Generic mfg., letrozole / Generic mfg.
Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials group ANZ 1401 ELIMINATE trial. (Frankfurt Hall) - Mar 19, 2022 - Abstract #ESMOBC2022ESMO_BC_461;
ELIMINATE demonstrated a non-significant improvement in down-staging to pathologic stage 0 or 1A in luminal breast cancer with concurrent neoadjuvant chemotherapy and AI therapy. An additional 9% patients receiving CET reached an RCB score < 2 but BCS rates were similar in both groups.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Trial initiation date, Metastases: OMPCa-ENSURE: Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer (clinicaltrials.gov) - Mar 16, 2022
P2, N=160, Recruiting, Sponsor: Fudan University
An additional 9% patients receiving CET reached an RCB score < 2 but BCS rates were similar in both groups. Initiation date: Jan 2022 --> Apr 2022
- || leuprorelin depot / Generic mfg.
Clinical, Journal: Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial. (Pubmed Central) - Mar 15, 2022
P3
This randomized clinical trial, conducted at the Shanghai Jiao Tong University Affiliated Shanghai Sixth People's Hospital and Zhejiang Cancer Hospital in China, was an open-label trial involving premenopausal women aged 18 to 49 years with operable stage I to III breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned in 2 parallel groups: treatment with chemotherapy with or without GnRHa...In patients randomized to receive GnRHa, 3.6 mg of goserelin or 3.75 mg of leuprorelin was injected subcutaneously once every 28 days from 1 to 2 weeks before the first cycle of chemotherapy to 4 weeks after the last cycle of chemotherapy...This randomized clinical trial found that administering GnRHa in treatment with chemotherapy for premenopausal patients with breast cancer reduces the risk of POI, which promotes the recovery of ovarian function. ClinicalTrials.gov Identifier: NCT02518191.
- || everolimus / Generic mfg.
Clinical, P2 data, Journal: Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators: A Phase 2 Randomized Clinical Trial. (Pubmed Central) - Mar 12, 2022
P2
To compare the effectiveness of everolimus plus letrozole vs letrozole alone in premenopausal women with HR-positive/ERBB2-negative advanced breast cancer who experienced disease progression while receiving SERMs...Both groups received goserelin, 3.6 mg, subcutaneously on day 1 of each 28-day cycle...The results revealed that everolimus was effective even among patients receiving treatment with the same endocrine agent after disease progression. ClinicalTrials.gov Identifier: NCT02313051.
- || goserelin acetate / Generic mfg., tamoxifen / Generic mfg., exemestane / Generic mfg.
I had a choice to take Tamoxifen or Exemestane. I chose Exemestane and also have Zoladex monthly. I heard Tamoxifen is very hard on you. (Twitter) - Mar 11, 2022
- | leuprorelin depot / Generic mfg.
Journal: Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy. (Pubmed Central) - Mar 9, 2022
The recovery patterns of hormonal profiles after short-term (12 weeks) neoadjuvant ADT differ between GnRH antagonists and GnRH agonists. The choice between these drugs matters and may have a clinical impact depending on the primary objective of ADT.
- ipatasertib (RG7440) / Roche
Establishment and characterization of two novel patient-derived organoid xenograft models of advanced prostate cancer (Section 9) - Mar 9, 2022 - Abstract #AACR2022AACR_5675;
We have successfully generated two novel PDOX models, which highly resemble the original patients’ tumor and can be further cultured as organoids. These models are representative of relevant clinical and molecular subtypes of advanced PCa, providing further opportunities for translational studies.
- || leuprorelin depot / Generic mfg.
Clinical, Journal: Adding short-term androgen deprivation therapy to RT in men with localized prostate cancer: long-term update of the NRG/RTOG 9408 randomized clinical trial. (Pubmed Central) - Mar 8, 2022
These models are representative of relevant clinical and molecular subtypes of advanced PCa, providing further opportunities for translational studies. Further follow-up demonstrates that OS converges at approximately 15 years, by which point the administration of 4 months of ADT had conferred an estimated additional 6 months of life.
- ||| Emcyt (estramustine) / Pfizer, Nippon Shinyaku
Trial completion date, Metastases: Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse (clinicaltrials.gov) - Mar 8, 2022
P3, N=413, Active, not recruiting, Sponsor: UNICANCER
Further follow-up demonstrates that OS converges at approximately 15 years, by which point the administration of 4 months of ADT had conferred an estimated additional 6 months of life. Trial completion date: Dec 2021 --> Dec 2022
- || goserelin acetate / Generic mfg.
So does that mean that Zoladex remains the standard of care. (Twitter) - Mar 7, 2022
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer (clinicaltrials.gov) - Mar 3, 2022
P2, N=55, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Dec 2021 --> Dec 2022 Trial completion date: Feb 2022 --> Dec 2022
- | Kisqali (ribociclib) / Novartis
Biomarker, Phase classification: LEANORA: Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (clinicaltrials.gov) - Mar 3, 2022
P4, N=36, Recruiting, Sponsor: Georgetown University
Trial completion date: Feb 2022 --> Dec 2022 Phase classification: P=N/A --> P4
- | Firmagon (degarelix) / Astellas, Ferring
Enrollment change: Degarelix in the Treatment of Endometriosis Recurrence (clinicaltrials.gov) - Feb 28, 2022
P3, N=360, Completed, Sponsor: Centre for Endocrinology and Reproductive Medicine, Italy
Phase classification: P=N/A --> P4 N=100 --> 360
- || Herceptin (trastuzumab) / Roche
Clinical, Journal: Ovarian tissue cryopreservation in a patient with breast cancer during pregnancy: a case report. (Pubmed Central) - Feb 26, 2022
OTC for fertility preservation in patients with PrBC does not delay breast surgery, radiotherapy or chemotherapy, which is essential for effective treatment of breast cancer. We assess this method as a promising fertility preservation method which was used here for the first time worldwide in a patient who developed breast cancer during pregnancy.
- || Kisqali (ribociclib) / Novartis
Trial initiation date, Metastases: NEOLETRIB: Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (clinicaltrials.gov) - Feb 25, 2022
P2, N=100, Not yet recruiting, Sponsor: University Hospital, Akershus
We assess this method as a promising fertility preservation method which was used here for the first time worldwide in a patient who developed breast cancer during pregnancy. Initiation date: Jan 2022 --> Apr 2022
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: BTCRC-HN17-111: Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma (clinicaltrials.gov) - Feb 24, 2022
P2, N=20, Recruiting, Sponsor: Manish Patel
Initiation date: Jan 2022 --> Apr 2022 Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2022 --> Jan 2023
- ||| goserelin acetate / Generic mfg., bicalutamide / Generic mfg.
Enrollment closed, Enrollment change, Metastases: A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. (clinicaltrials.gov) - Feb 24, 2022
P4, N=9, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2022 --> Jan 2023 Recruiting --> Active, not recruiting | N=871 --> 9
- | Epidaza (chidamide) / Chipscreen
New P2/3 trial: Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer (clinicaltrials.gov) - Feb 23, 2022
P2/3, N=130, Not yet recruiting, Sponsor: Shengjing Hospital
- || zoledronic acid / Generic mfg.
Clinical, Journal: Oestradiol Contributes to Differential Antitumour Effects of Adjuvant Zoledronic Acid Observed Between Pre- and Post-Menopausal Women. (Pubmed Central) - Feb 19, 2022
In conclusion, oestradiol contributes to altered antitumour effects of Zol observed between pre- and post-menopausal women. However, other immunological/microenvironmental factors are also likely to contribute to this phenomenon.
- Kisqali (ribociclib) / Novartis
A Case Report of Ribociclib-Induced Pneumonitis (Area F, Hall F (North Building, Exhibition Level), Moscone Center) - Feb 19, 2022 - Abstract #ATS2022ATS_991;
Ribociclib was discontinued and the patient improved symptomatically with return to baseline level of function.Reports of CDK 4/6 inhibitor drug-associated lung injury are limited There has been only one case report outside of clinical trials of Ribociclib pneumonitis.7 As these drugs become more commonly used, it is important for clinicians to be aware of this potentially fatal drug associated lung injury. Treatment with drug cessation has varying responses from recovery like in our patient to death.
- ||| Abiraterone + rucaparib + nivolumab + apalutamide + Zoladex + anti-LAG3 + docetaxel. ARuNAZaD. Yes, I see where you’re going with this. #GU22 #ProstateCancer #pcsm (Twitter) - Feb 19, 2022
- | Cetrotide (cetrorelix) / EMD Serono
Journal: Magnetic solid-phase extraction of high molecular weight peptides using stearic acid-functionalized magnetic hydroxyapatite nanocomposite: determination of some hypothalamic agents in biological samples. (Pubmed Central) - Feb 17, 2022
Under optimum conditions, the proposed method (MSPE-HPLC-UV) represented favorable linearity with R ≥ 0.9987, suitable intra- and inter-day precisions (RSD ≤ 6.9% and RSD ≤ 8.1%, respectively, n = 3), and limits of detection and quantification in the range of 0.75-1.12 ng mL and 2.50-3.75 ng mL, respectively. Eventually, the proposed method was used for the extraction and quantification of target therapeutic peptides in plasma and urine samples, and satisfactory relative recoveries were achieved in the range of 90.6-110.3%.
- | Firmagon (degarelix) / Astellas, Ferring
Enrollment closed, Monotherapy: High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Feb 16, 2022
P1/2, N=163, Active, not recruiting, Sponsor: Stanford University
Eventually, the proposed method was used for the extraction and quantification of target therapeutic peptides in plasma and urine samples, and satisfactory relative recoveries were achieved in the range of 90.6-110.3%. Suspended --> Active, not recruiting
- | goserelin acetate / Generic mfg.
Preclinical, Journal: Goserelin/PLGA solid dispersion used to prepare long-acting microspheres with reduced initial release and reduced fluctuation of drug serum concentration in vivo. (Pubmed Central) - Feb 16, 2022
Pharmacodynamics study also showed potential effect of F5 microspheres on inhibiting the secretion of testosterone in male rats. HME-O/W method is potential to establish long-acting PLGA microspheres (loading water-soluble drug) , exhibiting stable drug serum concentration in vivo, and without large concentration fluctuation or serious pain/side effects.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P2 trial, Metastases: Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM) (clinicaltrials.gov) - Feb 16, 2022
P2, N=75, Not yet recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- || goserelin acetate / Generic mfg.
Usually lueprolide or goserelin (whatever is available) (Twitter) - Feb 16, 2022
- || Ibrance (palbociclib) / Pfizer, gedatolisib (PF-05212384) / Celcuity
Enrollment closed, Trial completion date, Trial primary completion date: Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer (clinicaltrials.gov) - Feb 9, 2022
P1, N=18, Active, not recruiting, Sponsor: Hoffman Oncology
HME-O/W method is potential to establish long-acting PLGA microspheres (loading water-soluble drug) , exhibiting stable drug serum concentration in vivo, and without large concentration fluctuation or serious pain/side effects. Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Feb 2022
- | Suprefact (buserelin acetate) / Sanofi, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
Enrollment open, Trial completion date: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - Feb 3, 2022
P3, N=2478, Recruiting, Sponsor: NRG Oncology
Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Mar 2022 | Trial primary completion date: Sep 2020 --> Feb 2022 Suspended --> Recruiting | Trial completion date: Dec 2038 --> Dec 2033
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Enrollment closed, HEOR, Real-world evidence, Real-world, Metastases: A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer (clinicaltrials.gov) - Feb 2, 2022
P=N/A, N=400, Active, not recruiting, Sponsor: Bayer
Suspended --> Recruiting | Trial completion date: Dec 2038 --> Dec 2033 Not yet recruiting --> Active, not recruiting
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas, Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring
New P2 trial, Metastases: OMPCa-ENSURE: Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer (clinicaltrials.gov) - Jan 27, 2022
P2, N=160, Recruiting, Sponsor: Fudan University
- ||| goserelin acetate / Generic mfg.
Trial primary completion date, Metastases: Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer (clinicaltrials.gov) - Jan 27, 2022
P3, N=94, Recruiting, Sponsor: Eurofarma Laboratorios S.A.
Not yet recruiting --> Active, not recruiting Trial primary completion date: Dec 2021 --> Dec 2022
- ||| goserelin acetate / Generic mfg.
Trial primary completion date: Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer (clinicaltrials.gov) - Jan 27, 2022
P3, N=68, Recruiting, Sponsor: Eurofarma Laboratorios S.A.
Trial primary completion date: Dec 2021 --> Dec 2022 Trial primary completion date: Dec 2021 --> Dec 2022
- ||| goserelin acetate / Generic mfg.
Enrollment open, Real-world evidence, Real-world: Zoladex (clinicaltrials.gov) - Jan 25, 2022
P=N/A, N=1000, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2021 --> Dec 2022 Not yet recruiting --> Recruiting
- | leuprolide acetate for depot suspension / Generic mfg.
New trial: Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect (clinicaltrials.gov) - Jan 25, 2022
P=N/A, N=200, Not yet recruiting, Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- | Enrollment open: GUIDANCE: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score (clinicaltrials.gov) - Jan 24, 2022
P3, N=2050, Recruiting, Sponsor: NRG Oncology
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Kisqali (ribociclib) / Novartis
Trial completion, Metastases: TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer (clinicaltrials.gov) - Jan 21, 2022
P1, N=7, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Xtandi (enzalutamide capsule) / Pfizer, Astellas, Eligard (leuprolide acetate) / Tolmar, Sanofi, Recordati
Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world, Metastases: A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer (clinicaltrials.gov) - Jan 19, 2022
P=N/A, N=400, Not yet recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial completion date: Jul 2022 --> Sep 2022 | Trial primary completion date: Jul 2022 --> Sep 2022
- |||||| Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma
Enrollment open, Metastases: A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy (clinicaltrials.gov) - Jan 12, 2022
P3, N=1256, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Trial completion date: Jul 2022 --> Sep 2022 | Trial primary completion date: Jul 2022 --> Sep 2022 Not yet recruiting --> Recruiting